Milestone Pharmaceuticals Inc. Common Shares (MIST) Stock
NASDAQ · MIST
0.80
Fundamentals
Market cap
$98.15M
Price / Earnings ratio
-1.2x
Price / Sales ratio
42.3x
Price / Book ratio
5.4x
Return on assets
-62.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Milestone Pharmaceuticals Q2 Earnings Call Highlights
NeutralMISTAugust 12, 2026
MarketBeatNeutral
Milestone Pharmaceuticals Q2 Earnings Call Highlights
MIST

Zacks Investment Research
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
NeutralMISTAugust 12, 2026
Zacks Investment ResearchNeutral
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
MIST

Zacks Investment Research
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
NeutralMISTJuly 29, 2026
Zacks Investment ResearchNeutral
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
MIST

MarketBeat
Milestone Pharmaceuticals Q1 Earnings Call Highlights
NeutralMISTMay 13, 2026
MarketBeatNeutral
Milestone Pharmaceuticals Q1 Earnings Call Highlights
MIST
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
2M1M6122160
Debt & Balance Sheet
Total assets
Total liabilities
2025
136M90M45M0
Revenue to Profit
2025$1.5M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-63.1M
Net incomeEarnings
No data available
% positive news of 7 articles
published over the past 14 days
Latest news

MarketBeat
Milestone Pharmaceuticals Q2 Earnings Call Highlights
NeutralMISTAugust 12, 2026
MarketBeatNeutral
Milestone Pharmaceuticals Q2 Earnings Call Highlights
MIST

Zacks Investment Research
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
NeutralMISTAugust 12, 2026
Zacks Investment ResearchNeutral
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
MIST

Zacks Investment Research
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
NeutralMISTJuly 29, 2026
Zacks Investment ResearchNeutral
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)
MIST

MarketBeat
Milestone Pharmaceuticals Q1 Earnings Call Highlights
NeutralMISTMay 13, 2026
MarketBeatNeutral
Milestone Pharmaceuticals Q1 Earnings Call Highlights
MIST

Zacks Investment Research
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
NeutralMISTMay 13, 2026
Zacks Investment ResearchNeutral
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
MIST

Zacks Investment Research
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
NeutralMISTJanuary 27, 2026
Zacks Investment ResearchNeutral
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
MIST

Stocktwits
MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns
NeutralMISTDecember 15, 2025
StocktwitsNeutral
MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns
MIST
About Milestone Pharmaceuticals Inc. Common Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees38
CEOMr. Joseph G. Oliveto M.B.A.
IPO DateMay 9, 2019
HeadquartersMontreal, QC
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph G. Oliveto M.B.A. | CEO, President & Executive Director | 1968 |
| Mr. Amit Hasija | CFO & Executive VP of Corporate Development | 1973 |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer | 1962 |
| Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor & Member of Scientific Advisory Board | 1962 |
| Mr. Jeffrey Nelson | Chief Operating Officer | 1981 |
| Mr. David Sandoval | General Counsel & Chief Compliance Officer | 1978 |
| Mr. Roshan Girglani | Vice President of Marketing | — |
| Mr. Jeff Moore | Vice President of Sales | — |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor & Member of the Scientific Advisory Board | 1956 |
| Dr. Guy Rousseau | SVP of Regulatory Affairs and Quality Management | — |
Fundamentals
Valuation
Market cap$98.15M
Price-to-sales ratio42.25
Price-to-book value5.43
Price-earnings ratio-1.20
Return on Equity-339.00%
Return on Sales-3438.00%
Return on Assets-62.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.68
Income Statement
Average volume1,486,614
EBITDA$-61.18M
1 year high (52w)$3.06
1 year low (52w)$0.78
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$5.50
Est return
597.08%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.8 | -0.2 | -4.0 | +16.1 | ||||||||
| 2022 | -3.9 | -24.4 | +31.0 | -2.9 | -8.8 | +13.3 | +27.1 | +18.6 | +4.6 | -44.7 | -2.6 | -18.5 |
| 2023 | -9.6 | -21.4 | +25.5 | -8.8 | +8.8 | -23.0 | -3.6 | -15.5 | +14.8 | -14.1 | +19.3 | -47.3 |
| 2024 | -11.1 | +0.6 | +11.2 | -9.8 | -6.3 | -12.6 | +7.5 | +2.2 | +9.4 | -3.3 | +38.2 | +18.0 |
| 2025 | -9.2 | -16.8 | -51.5 | +73.7 | +22.7 | +12.1 | -22.9 | +28.7 | +8.7 | -6.3 | +45.4 | -24.9 |
| 2026 | -6.8 | -12.8 | -31.2 | +37.4 | -24.1 | -1.5 | -15.9 | +3.6 | -30.7 |



